[3] Her opinions and commentary have been featured in a variety of international media, including New York Times,[4] The Globe and Mail (Canada),[5] The Daily Nation (Kenya),[6] Nature News[7] and the South African Medical Journal.
From 1999 to 2002, Rosenberg was the scientific director for the HIV Prevention Trials Network (HPTN) at Family Health International (FHI).
[citation needed] Rosenberg provides vision, leadership and direction to IPM, which has become a leading product development partnership in the HIV prevention field.
Under Dr. Rosenberg's leadership, IPM has entered into six non-exclusive, royalty-free licenses with five major pharmaceutical companies — Bristol-Myers Squibb, Gilead Sciences, Merck & Co., Pfizer and Tibotec Pharmaceuticals (division of Johnson & Johnson) — to develop, manufacture and distribute eight antiretroviral (ARV) products as microbicides in developing countries.
[11] In 2011, IPM will initiate a Phase III clinical program to evaluate the dapivirine vaginal ring, an antiretroviral-based product that could potentially provide women with HIV protection for a month or longer.